Inactivity of imatinib in gastrointestinal stromal tumors (GISTs) harboring a KIT activation-loop domain mutation (exon 17 mutation pN822K)

Inactivity of imatinib in gastrointestinal stromal tumors (GISTs) harboring a KIT activation-loop domain mutation (exon 17 mutation pN822K)

Gianluca Spitaleri,1 Roberto Biffi,2 Massimo Barberis,3 Caterina Fumagalli,3 Francesca Toffalorio,1 Chiara Catania,1 Cristina Noberasco,1 Chiara Lazzari,1 Filippo de Marinis,1 Tommaso De Pas41Division of Chest Medical Oncology, 2Division of Abdominal Surgery, 3Division of Pathology, 4Oncology Unit o...

Full description

Bibliographic Details
Main Authors:	Spitaleri G, Biffi R, Barberis M, Fumagalli C, Toffalorio F, Catania C, Noberasco C, Lazzari C, de Marinis F, De Pas T
Format:	Article
Language:	English
Published:	Dove Medical Press 2015-08-01
Series:	OncoTargets and Therapy
Online Access:	http://www.dovepress.com/inactivity-of-imatinib-in-gastrointestinal-stromal-tumors-gists-harbor-peer-reviewed-article-OTT

Similar Items

Antitumor activity of sorafenib and imatinib in a patient with thymic carcinoma harboring c-KIT exon 13 missense mutation K642E
by: Catania C, et al.
Published: (2014-05-01)

Significance of KIT and PDGFRA mutations in gastric gist imatinib - naive surgically treated patients
by: Ebrahimi Keramatollah, et al.
Published: (2019-01-01)

Update on management of GIST and postsurgical use of imatinib
by: E Pennacchioli, et al.
Published: (2010-08-01)

Postfoundational practical theology as public Christol̶o̶g̶y̶
by: Johann-Albrecht Meylahn
Published: (2014-08-01)

KIT exon 11 and PDGFRA exon 18 gene mutations in gastric GIST: proposal of a short panel for predicting therapeutic response
by: Denise Barcelos, et al.
Published: (2018-11-01)

Sweden and the Papacy : 822-1248
by: Oppermann, C. J. A.
Published: (1931)

Not all 557/558 codons mutations have the same prognostic influence on recurrence-free survival: breaking the exon 11 mutations in gastrointestinal stromal tumors (GISTs)
by: Lorena Incorvaia, et al.
Published: (2021-09-01)

Update on the treatment of gastrointestinal stromal tumors (GISTs): role of imatinib
by: Richard Quek, et al.
Published: (2010-02-01)

Antitumor effect of the tyrosine kinase inhibitor nilotinib on gastrointestinal stromal tumor (GIST) and imatinib-resistant GIST cells.
by: Hiroyuki Sako, et al.
Published: (2014-01-01)

A V530I Mutation in c-KIT Exon 10 Is Associated to Imatinib Response in Extraabdominal Aggressive Fibromatosis
by: Jean-Emmanuel Kurtz, et al.
Published: (2010-01-01)

cKIT Mutations in GISTs and Other Malignancies in Thailand
by: Thongbliew Prempree, et al.
Published: (2006-03-01)

Succinate dehydrogenase deficiency in a PDGFRA mutated GIST
by: Martin G. Belinsky, et al.
Published: (2017-08-01)

Imatinib as adjuvant therapy for high risk GIST: a case report
by: Patrizia Lista, et al.
Published: (2015-10-01)

Tumor volume as an alternative response measurement for imatinib treated GIST patients.
by: Gaia Schiavon, et al.
Published: (2012-01-01)

Preoperative imatinib mesylate (IM) for huge gastrointestinal stromal tumors (GIST)
by: Sumin Tang, et al.
Published: (2017-04-01)

Adjuvant therapy with imatinib mesilate in a patient with intermediate risk GIST
by: Giuseppe Aprile
Published: (2015-10-01)

Proteomic detection of a large amount of SCGFα in the stroma of GISTs after imatinib therapy
by: Gronchi Alessandro, et al.
Published: (2011-09-01)

Gene Expression Profiling of PDGFRA Mutant GIST Reveals Immune Signatures as a Specific Fingerprint of D842V Exon 18 Mutation
by: Valentina Indio, et al.
Published: (2020-06-01)

Mutations Associated with Imatinib Mesylate Resistance - Review
by: Linev Alexandar J., et al.
Published: (2018-12-01)

Correction: Tumor Volume as an Alternative Response Measurement for Imatinib Treated GIST Patients
by: Gaia Schiavon, et al.
Published: (2013-01-01)

Rapidly progressive dyspnea in gastrointestinal stromal tumor (GIST) with imatinib cardiac toxicity
by: Adnan Asif Parvez Ghias, et al.
Published: (2018-03-01)

Role of imatinib in the management of early, operable, and advanced GI stromal tumors (GISTs)
by: John T Vetto
Published: (2009-06-01)

Correction: Tumor Volume as an Alternative Response Measurement for Imatinib Treated GIST Patients.
by: Gaia Schiavon, et al.
Published: (2013-01-01)

Imatinib dose optimisation following the disease progression in a patient with metastatic GIST
by: Mariangela Parodi, et al.
Published: (2015-10-01)

Imatinib and gastrointestinal stromal tumor (GIST): a selective targeted therapy Imatinib y tumor del estroma gastrointestinal (GIST): un tratamiento selectivo frente a una diana molecular
by: A. Fernández, et al.
Published: (2004-10-01)

Tumor-targeting Salmonella typhimurium A1-R suppressed an imatinib-resistant gastrointestinal stromal tumor with c-kit exon 11 and 17 mutations
by: Kentaro Miyake, et al.
Published: (2018-06-01)

Inhibition of FGF2-Mediated Signaling in GIST—Promising Approach for Overcoming Resistance to Imatinib
by: Sergei Boichuk, et al.
Published: (2020-06-01)

Imatinib-induced liver cirrhosis in a patient with advanced gastrointestinal stroma tumor (GIST)
by: Seidel Christoph, et al.
Published: (2012-05-01)

Do Not Be Fooled by Fancy Mutations: Inflammatory Fibroid Polyps Can Harbor Mutations Similar to Those Found in GIST
by: Bodil Bjerkehagen, et al.
Published: (2013-01-01)

GIST rectal Rectal GIST
by: Z. Valera Sánchez, et al.
Published: (2008-06-01)

Neoadjuvant imatinib in patients with locally advanced non metastatic GIST in the prospective BFR14 trial
by: Cupissol Didier, et al.
Published: (2011-02-01)

Gastrointestinal stromal tumor (GIST) recurrence following surgery: review of the clinical utility of imatinib treatment
by: Isabelle Deshaies, et al.
Published: (2010-09-01)

Targeting of FGF-Signaling Re-Sensitizes Gastrointestinal Stromal Tumors (GIST) to Imatinib In Vitro and In Vivo
by: Sergei Boichuk, et al.
Published: (2018-10-01)

Mutation status of refractory to imatinib patients with chronic myeloid leukemia
by: E. G. Ovsyannikova, et al.
Published: (2014-07-01)

Mutation status of refractory to imatinib patients with chronic myeloid leukemia
by: E. G. Ovsyannikova, et al.
Published: (2014-07-01)

N822K- or V560G-mutated KIT activation preferentially occurs in lipid rafts of the Golgi apparatus in leukemia cells
by: Yuuki Obata, et al.
Published: (2019-09-01)

Type and Gene Location of <i>KIT</i> Mutations Predict Progression-Free Survival to First-Line Imatinib in Gastrointestinal Stromal Tumors: A Look into the Exon
by: Lorena Incorvaia, et al.
Published: (2021-02-01)

Mutations primarily alter the inclusion of alternatively spliced exons
by: Pablo Baeza-Centurion, et al.
Published: (2020-10-01)

Dramatic regression and bleeding of a duodenal GIST during preoperative imatinib therapy: case report and review
by: Schwandner Thilo, et al.
Published: (2010-06-01)

Comparison of uncommon EGFR exon 21 L858R compound mutations with single mutation
by: Peng L, et al.
Published: (2015-04-01)